|1.||González, Gisela: 2 articles (01/2011 - 01/2010)|
|2.||Neninger Vinageras, Elia: 1 article (01/2015)|
|3.||Crombet Ramos, Tania: 1 article (01/2015)|
|4.||Lage Davila, Agustin: 1 article (01/2015)|
|5.||Rodríguez, Pedro Camilo: 1 article (01/2015)|
|6.||Garcia Verdecia, Beatriz: 1 article (01/2015)|
|7.||Herrera, Zaima Mazorra: 1 article (07/2014)|
|8.||Ramos, Tania Crombet: 1 article (07/2014)|
|9.||Kananathan, Ratnavelu: 1 article (12/2012)|
|10.||Cheng, Jian Y: 1 article (12/2012)|
05/09/2012 - "This study showed evidences that intramuscular administration during 26 weeks of CIMAvax-EGF at doses up to 15× human total dose is well tolerated in rats and it has a clinical importance since this long lasting study in relevant species allows to treat cancer patients with tumors during long periods with relative weight safety margin."
01/01/2010 - "CIMAvax EGF's benefits in earlier NSCLC stages and in other tumor locations, as well as in patients unfit for chemotherapy, need to be evaluated. "
01/01/2015 - "CIMAvax-EGF is a therapeutic cancer vaccine composed by recombinant EGF conjugated to a carrier protein and emulsified in Montanide ISA51. "
01/01/2011 - "CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. "
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/01/2015 - "CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer."
12/01/2012 - "CIMAvax EGF vaccine for stage IIIb/IV non-small cell lung carcinoma."
01/01/2010 - "CIMAvax EGF is a therapeutic anticancer vaccine developed entirely in Cuba and licensed in Cuba for use in adult patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). "
01/01/2010 - "Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy."
07/01/2014 - "To address this issue, the current review summarizes the main clinical and immunological results obtained with two different therapeutic vaccines used in advanced non-small-cell lung cancer patients, inducing an immune response against epidermal growth factor (CIMAvax-EGF) and NGcGM3 ganglioside (racotumomab). "
|1.||Epidermal Growth Factor (EGF)
|3.||montanide ISA 51
|1.||Drug Therapy (Chemotherapy)